Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Perioperative vorasidenib or ivosidenib demonstrated sustained clinical benefit in patients with predominantly non-enhancing IDH1-mutant diffuse glioma.

Perioperative Vorasidenib and Ivosidenib Remain Effective, Safe in IDH1+ Diffuse Glioma 

Mirdametinib led to sustained, significant, and clinically meaningful improvements in HRQOL in adults and children with NF1-PN.

Mirdametinib Improves HRQOL in Adult and Pediatric Patients With NF1-PN

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.
 

Dr Kumethaker on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease  

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Articles

Researchers at Moffitt Cancer Center published an article in Cancer Cell showing that necroptosis-mediated immune suppression occurs through release of IL-1α.

Moffitt Study Shows How Cancer Cell Death May Harm the Immune System and Promote Tumor Growth

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

CM24 plus nivolumab and chemotherapy demonstrated an improvement in efficacy vs chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.

CM24 Plus Nivolumab and Chemo Displays Efficacy vs Chemo Alone in Metastatic PDAC

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Peter Martin, MD, discusses the current role of BTK inhibitors in MCL and how future research may solidify the use of these agents in this disease.  

BTK Inhibitor–Based Combinations Represent the Future of MCL Management

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Rimas V. Lukas, MD, discusses the potential role for eflornithine plus lomustine in recurrent grade 3 IDH-mutant astrocytoma.  

Eflornithine Plus Lomustine Demonstrates Clinically Meaningful Survival Benefits in Grade III IDH-Mutant Astrocytoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma

Clinical

Video Series

Real-World Evidence on Second-Line Therapy Selection and Outcomes

Videos

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss the role of tyrosine kinase inhibitors in unresectable hepatocellular carcinoma, second-line treatment options, and recent clinical trials.

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Examining the Role of Liver Function in HCC

The key opinion leaders discuss staging systems they use in clinical practice and their effectiveness in creating treatment algorithms, particularly with respect to Child-Pugh scores.

HCC Staging: Improving Treatment Strategies

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, review locoregional therapies for hepatocellular carcinoma, including transarterial chemoembolization (TACE) and radioembolization.

Locoregional Therapies for Intermediate-Stage HCC

Medical experts discuss the LAUNCH study, EMERALD-1, and LEAP-012 trials, providing updates on the progress and findings that influence the treatment paradigm for hepatocellular carcinoma.

HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

The panelists examine the effectiveness of transarterial chemoembolization (TACE) in treating hepatocellular carcinoma in patients with intermediate-stage disease and discuss the future prospects for these patients. 

Emerging Therapies in Intermediate-Stage HCC 

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma. 

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials 

The panelists discuss factors that may preclude patients from receiving certain therapies, such as cardiovascular comorbidities, which may pose an immediate threat to the patient's life.

Comorbidity Considerations for HCC Treatment

Medical experts discuss the selection of second-line treatments for patients who experience disease progression while on first-line therapy, highlighting the potential for deterioration in performance status and liver function.

The Evolving Landscape of Second-Line Therapies in HCC Management

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss a novel therapy that, although not practice-changing, provides an additional treatment option for patients with hepatocellular carcinoma. 

Additional Second-Line Treatments for HCC

Medical experts discuss how the time to progression, progression patterns, and real-world data influence the provider's choice of treatment for patients with hepatocellular carcinoma. 

Real-World Evidence on Second-Line Therapy Selection and Outcomes 

In their concluding remarks, Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, express their hopes for future advancements in hepatocellular carcinoma (HCC) treatment, including cellular-based therapies, antibody-drug conjugates, and an increased focus on neoadjuvant studies.

Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 1.Examining the Role of Liver Function in HCC

EP: 2.HCC Staging: Improving Treatment Strategies

EP: 3.Locoregional Therapies for Intermediate-Stage HCC

EP: 4.HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

EP: 5.Emerging Therapies in Intermediate-Stage HCC

EP: 6.Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

EP: 7.Comorbidity Considerations for HCC Treatment

EP: 8.The Evolving Landscape of Second-Line Therapies in HCC Management

EP: 9.Additional Second-Line Treatments for HCC

EP: 10.Real-World Evidence on Second-Line Therapy Selection and Outcomes

EP: 11.Pioneering Breakthroughs in HCC Treatment

Latest Conference Coverage